Trice Medical
Trice Medical is a privately held medical device company that develops and sells FDA-cleared minimally invasive ultrasonic tenotomy systems, endoscopic release devices, and disposable needle arthroscopes for orthopedic surgeons, sports medicine physicians, podiatrists, and hospitals treating chronic tendinopathy, carpal tunnel syndrome, and diabetic foot ulcers.
- Company typePrivate
- Founded2012
- HeadquartersMalvern, United States
- Headcount11–50
- GTM typeB2B
- OfferingHardware or Manufacturing
What Trice Medical does
Trice Medical is a privately held medical device company specializing in minimally invasive orthopedic and sports medicine technologies. Founded around 2012 and headquartered in Malvern, Pennsylvania, with a secondary office in Lake Forest, California, the company develops and commercializes FDA-cleared ultrasonic tenotomy systems, endoscopic release devices, and single-use needle arthroscopes. Its portfolio targets orthopedic surgeons, sports medicine physicians, podiatrists, hand surgeons, hospitals, and ambulatory surgery centers performing procedures for chronic tendinopathy, carpal tunnel syndrome, cubital tunnel syndrome, plantar fasciitis, diabetic foot ulcers, and related musculoskeletal conditions. The company has grown through strategic acquisitions, including Seg-WAY Orthopedics in 2019 and Tenex Health in April 2021, consolidating complementary minimally invasive technologies under a single platform with sub-brands Tenex, Seg-WAY, and mi-eye.
The company's core technology platforms include the Tenex Health TX System and its 2024-cleared Tenex 2nd Generation System, which use ultrasonic cutting technology for percutaneous tissue removal through a 3-5mm mini-incision; the Seg-WAY Endoscopic Release Systems for carpal tunnel, cubital tunnel, plantar fasciitis, and gastrocnemius procedures; and the mi-eye 3 disposable needle arthroscopes (0°, 15°, and 25° configurations) paired with the mi-tablet 3 portable high-resolution imaging platform. Trice has secured an extensive portfolio of over 25 US patents covering MicroTip designs, needlescope technology, and endoscopic release systems. Clinical evidence supporting the platform includes 240,000+ Tenex procedures performed since 2012, peer-reviewed studies showing ≥85% patient satisfaction for chronic tendon treatment, 96% diabetic foot ulcer healing rates in under 3.5 weeks, and <5% recurrence rates compared to 40-65% for conventional treatments.
Trice's business model centers on one-time sales of capital equipment (reusable console systems and imaging platforms) and high-margin disposable medical devices (TX MicroTips, Seg-WAY kits, mi-eye needlescopes) sold through a direct US field sales force targeting healthcare facilities and physician offices, with exclusive international distribution handled by Bioventus Inc. following an August 2021 strategic investment and partnership that also includes co-development of integrated nerve stimulation products. The company has raised approximately $106 million in funding across multiple rounds since 2012, with key investors including Bioventus, HealthQuest Capital, Safeguard Scientifics, Smith & Nephew, Charter Capital Partners, and BioStar Capital. Pricing is not publicly disclosed but appears to be quote-based for healthcare facilities. With 11-50 employees, an enterprise field sales motion, and a medical advisory board of 10 key opinion leaders from institutions such as Rothman Orthopaedics, Montefiore Health, and the University of Iowa Healthcare, Trice operates a focused, capital-efficient specialty medical device model.
Trice Medical firmographics
Firmographics- Name
- Trice Medical
- Legal name
- Trice Medical, Inc.
- Website
- https://tricemedical.com
- Company type
- Private
- Founded year
- 2012
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Short description
- Trice Medical is a privately held medical device company that develops and sells FDA-cleared minimally invasive ultrasonic tenotomy systems, endoscopic release devices, and disposable needle arthroscopes for orthopedic surgeons, sports medicine physicians, podiatrists, and hospitals treating chronic tendinopathy, carpal tunnel syndrome, and diabetic foot ulcers.
- Ownership category
- akta.pro rank
Trice Medical industry classification
Industry- Product category
- Minimally Invasive Orthopedic Surgical Devices
- NAICS
- Surgical and Medical Instrument Manufacturing (339112), Surgical Appliance and Supplies Manufacturing (339113)
- SIC
- Surgical & Medical Instruments & Apparatus (3841)
- akta.pro primary industry
- Open & Minimally Invasive Surgical Instruments (Handheld, Laparoscopic, MIS) (HLAHADAA)
- akta.pro secondary industries
- Endoscopic Therapeutic & Access Devices (Trocars, dilators, biopsy/ablation tools) (HLAHADAN), Single-Use Surgical Devices & Procedure Packs (Disposable instruments, drapes, kits) (HLAHADAM), Surgical Navigation, Tracking & Intraoperative Guidance (Ortho/Neuro/ENT) (HLAHADAG)
Keywords
Where Trice Medical is headquartered
LocationHeadquarters
- HQ city
- Malvern
- HQ country
- United States
- HQ region
- North America
Offices3 records
Markets served
Trice Medical business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Personnel, Operations, Technology or R&D, Marketing or Sales, Supply Chain, Others
Revenue model
- Medical Device Sales: Sale of disposable medical devices including Tenex Health TX MicroTips (TX1, TX2, TXB), Seg-WAY endoscopic instruments (ECTR-d kits, ECTR, ECuTR, EGR, EPF), and mi-eye 3 needlescopes. Products are sold to hospitals, ambulatory surgery centers, and physician offices for use in minimally invasive orthopedic and sports medicine procedures.
- Capital Equipment Sales: Sale of reusable console systems (Tenex 2nd Generation Console, mi-tablet 3 imaging platform) to healthcare facilities, along with associated procedural instrument trays and disposable components.
Go-to-market motion2 records
Distribution channels2 records
Marketing channels6 records
Trice Medical product offering
Product offeringCore offering
Trice Medical develops and manufactures minimally invasive medical devices for orthopedic and sports medicine procedures. Its portfolio centers on three proprietary platforms: the Tenex ultrasonic tenotomy system for percutaneous removal of diseased tendon, bone, and treatment of diabetic foot ulcers; the Seg-WAY family of single-portal endoscopic release systems for carpal tunnel, cubital tunnel, plantar fasciitis, and gastrocnemius procedures; and the mi-eye single-use needle arthroscope line paired with the mi-tablet 3 portable imaging platform. Products are sold to hospitals, ambulatory surgery centers, and physician offices through a direct US sales force and through Bioventus internationally.
Product overview
Trice Medical offers a portfolio of minimally invasive medical technologies for orthopedic and sports medicine procedures. The portfolio centers on three core technology platforms: Tenex (ultrasonic tenotomy systems for treating chronic tendinopathy, bone spurs, and diabetic foot ulcers), Seg-WAY (endoscopic release systems for carpal tunnel, cubital tunnel, plantar fasciitis, and gastrocnemius procedures), and mi-eye (disposable needle arthroscopes for diagnostic and operative procedures). The Tenex 2nd Generation System is the latest ultrasonic platform building on the established Tenex Health TX technology. Seg-WAY products include both disposable (ECTR-d) and reusable (ECTR, ECuTR, EGR, EPF) endoscopic release systems. The mi-eye 3 family includes 0°, 15°, and 25° single-use needlescopes that connect to the mi-tablet 3 high-resolution imaging platform. Trice Medical acquired Tenex Health in 2021 and Seg-WAY Orthopedics in 2019, consolidating these complementary minimally invasive technologies.
Differentiator
Problem solved
Functional benefit
Brands
- Tenex: Minimally invasive ultrasonic tenotomy system for treatment of chronic tendon pain, bone spurs, calcific deposits, and diabetic foot ulcers
- Seg-WAY
- mi-eye
- mi-tablet
Products and services
- Tenex Health TX System FDA-cleared ultrasonic tenotomy system using advanced ultrasonic cutting technology for percutaneous removal of diseased soft and hard tissue through a 3-5mm mini-incision under local anesthesia, treating chronic tendinopathy, calcific tendonitis, and bone spurs. For orthopedic surgeons, sports medicine physicians, podiatrists, and hand surgeons.
- Tenex 2nd Generation System Next-generation ultrasonic platform building on the Tenex Health TX technology with longer MicroTip options for deeper anatomical access (shoulder, hip), redesigned console with advanced power settings, single-step MicroTip cassette loading, expanded aspiration/irrigation controls, and integrated case tracking.
- TX MicroTip for Soft Tissue (TX1) Disposable ultrasonic handpiece (TX1) for treating tendinopathy and calcification in tendons via ultrasound-guided percutaneous cutting and removal of diseased tissue through a mini-incision.
- TX MicroTip for Hard Tissue (TX-Bone) Disposable ultrasonic MicroTip for percutaneous removal of bone spurs, calcific deposits, and osteophytes; also indicated for diabetic foot ulcer treatment.
- Tenex Diabetic Foot Ulcer Application Single-procedure application using the TX-Bone MicroTip to remove bony prominence and unhealthy tissue under the wound without entering or expanding the wound area, addressing underlying causes of diabetic foot ulcers.
- Seg-WAY Endoscopic Release Systems Family of minimally invasive single-portal endoscopic release systems for upper and lower extremities, including carpal tunnel, cubital tunnel, plantar fasciitis, and gastrocnemius procedures. Features independent scope and blade operation for enhanced visualization.
- Seg-WAY ECTR-d (Endoscopic Carpal Tunnel Release Disposable) First fully disposable endoscopic carpal tunnel release system designed to properly position the incision in the Ulnar Safe Zone, enabling ECTR under local anesthetic with enhanced efficiency and safety.
- Seg-WAY ECTR (Endoscopic Carpal Tunnel Release Reusable) Reusable endoscopic carpal tunnel release system with anatomy-specific design and enhanced visualization through rasp and probe capabilities before ligament release.
- Seg-WAY ECuTR (Endoscopic Cubital Tunnel Release) Endoscopic cubital tunnel release system allowing safe viewing of entire ligament from above and below through controlled portals; only system where scope and blade work independently.
- Seg-WAY EGR (Endoscopic Gastrocnemius Recession) Endoscopic gastrocnemius recession system providing greater control and visualization with tactile feel of an endoscopic scalpel in a minimally invasive approach.
- Seg-WAY EPF (Endoscopic Plantar Fasciitis Release)
Quantifiable outcome
- 240,000+ procedures performed with Tenex Health TX System
- +6 more outcomes
Companies that use Trice Medical
Customer profileNamed customers10 records
Segments3 records
Ideal customer profiles2 records
Trice Medical technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature6 records
Trice Medical partnerships and signals
Strategic signalPartnerships
One partnership is on record.
- Bioventus Inc.coreBioventus Inc. completed a strategic investment in Trice Medical and acquired exclusive sales and distribution rights for Trice products outside the United States. The partnership includes a co-development agreement to integrate Trice's ultrasonic technologies with Bioventus' nerve stimulation products to accelerate product adoption and growth in the sports medicine and orthopedic markets.
Scale indicators10 records
Recent moves6 records
Expansion highlights6 records
Trice Medical competitors and assessment
Company assessmentBroad incumbents
- Arthrex: Arthrex is a large private medical device company specializing in minimally invasive orthopedic surgical technology, sports medicine, and arthroscopy. It directly overlaps Trice's mi-eye arthroscopy and Seg-WAY endoscopic product categories and serves the same orthopedic surgeon and sports medicine physician customers.
- Smith & Nephew: Smith & Nephew is a global medical device company with a leading sports medicine and orthopedic portfolio. It directly competes in arthroscopy, soft tissue repair, and minimally invasive orthopedic procedures, and is also a shareholder of Trice Medical via Series C participation.
- Stryker: Stryker is a global medical device leader with extensive sports medicine, orthopedic, and surgical equipment offerings. Its arthroscopy and sports medicine franchises overlap directly with Trice's Tenex, Seg-WAY, and mi-eye product categories.
- Conmed Corporation: Conmed is a publicly traded medical device company focused on general surgery, orthopedic, and sports medicine, with particular strength in arthroscopic resection and minimally invasive soft tissue procedures. Its product portfolio and customer base closely overlap Trice's Tenex and Seg-WAY lines.
- Integra LifeSciences: Integra LifeSciences is a medical device company with strong positions in regenerative tissue technologies, orthopedic, and surgical instruments. Its orthopedic and extremity surgery portfolios compete with Trice's sports medicine and minimally invasive offerings.
- Zimmer Biomet: Zimmer Biomet is a global orthopedic device leader with sports medicine, surgical, and biologics portfolios. Its extremity and sports medicine offerings compete with Trice's endoscopic release and ultrasonic tenotomy products for the same surgeon customers.
- DJO (Enovis): DJO, now part of Enovis, provides orthopedic devices and bracing focused on extremities, sports medicine, and rehabilitation. It serves many of the same orthopedic, podiatric, and sports medicine physicians that Trice targets with its Seg-WAY and Tenex systems.
Direct peers
- Misonix (Bioventus): Misonix, now part of Bioventus, develops ultrasonic surgical platforms for soft and hard tissue removal in neurosurgery, orthopedic, and wound care. It is the closest direct technology competitor to Trice's Tenex ultrasonic tenotomy platform, and Bioventus itself is Trice's exclusive international distributor.
- Anika Therapeutics: Anika Therapeutics develops and commercializes treatments for orthopedic conditions including hyaluronic acid injectables and regenerative therapies. It targets overlapping orthopedic and sports medicine indications treated by the same physician customers as Trice's Tenex and Seg-WAY systems.
Emerging players
- SonaCare Medical: SonaCare Medical develops high-intensity focused ultrasound (HIFU) and related minimally invasive surgical ablation technology for urological and other surgical applications. It represents an emerging alternative minimally invasive tissue ablation approach comparable in spirit to Trice's ultrasonic tenotomy platform.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat5 records
Key risks6 records
Key highlights7 records
Customer concentration
Trice Medical social profiles
Digital presenceTrice Medical financial estimates
Financial estimateRevenue estimate
Valuation estimate
Trice Medical leadership team
Management profileNumber of profiles
Profiles10 records
Trice Medical subsidiaries and ownership
Company hierarchySubsidiaries1 record
Trice Medical funding detail
Funding detailFunding overview
Funding rounds9 records
Investors7 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Trice Medical M&A and investment
M&A and investmentM&A2 records
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Trice Medical
What does Trice Medical do?
Trice Medical develops and manufactures minimally invasive medical devices for orthopedic and sports medicine procedures. Its portfolio centers on three proprietary platforms: the Tenex ultrasonic tenotomy system for percutaneous removal of diseased tendon, bone, and treatment of diabetic foot ulcers; the Seg-WAY family of single-portal endoscopic release systems for carpal tunnel, cubital tunnel, plantar fasciitis, and gastrocnemius procedures; and the mi-eye single-use needle arthroscope line paired with the mi-tablet 3 portable imaging platform. Products are sold to hospitals, ambulatory surgery centers, and physician offices through a direct US sales force and through Bioventus internationally.
Is Trice Medical a public or private company?
Trice Medical is a private company. It is classified as venture growth investor backed and is currently operating.
When was Trice Medical founded?
Trice Medical was founded in 2012. It employs 11 to 50 people.
Where is Trice Medical based?
Trice Medical is headquartered in Malvern, United States, in the North America region.
How does Trice Medical make money?
Two revenue lines are on record. Medical Device Sales are the primary driver. The others are capital Equipment Sales.
Who are Trice Medical's main competitors?
Broad incumbents on record are Arthrex, Smith & Nephew, Stryker, Conmed Corporation, Integra LifeSciences, Zimmer Biomet and DJO (Enovis). Direct peers are Misonix (Bioventus) and Anika Therapeutics. SonaCare Medical is listed as an emerging player.
Does Trice Medical have an API?
No public API is recorded for Trice Medical.
What industry is Trice Medical in?
Trice Medical's product category is Minimally Invasive Orthopedic Surgical Devices. Its primary akta.pro industry code is HLAHADAA, Open & Minimally Invasive Surgical Instruments (Handheld, Laparoscopic, MIS), with a secondary code of HLAHADAN, Endoscopic Therapeutic & Access Devices (Trocars, dilators, biopsy/ablation tools). Its NAICS code is 339112 and its SIC code is 3841.